Brief: Akeso Says NMPA Approved SNDA For Cadonilimab
05/06/2025 01:58
June 5 (Reuters) - Akeso Inc 9926.HK: NMPA APPROVED SNDA FOR CADONILIMAB AS FIRST-LINE TREATMENT FOR CERVICAL CANCER Further company coverage: 9926.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals